
Acute care and monitoring solutions
Health equity in pulse oximetry
Skin tone equity in tech performance
Medtronic believes healthcare technology shouldn’t discriminate. We’re leading with purpose, expanding access to healthcare, and making an impact toward achieving health equity.
Oxygen saturation is now considered the fifth vital sign across all areas of care. Our Nellcor™ pulse oximeters lead the way in equitable patient monitoring and offer greater SpO2 accuracy than Masimo for patients with dark skin tones.†,1 We are taking the impact further by advancing the technology, building lasting partnerships and investing in education to reduce the discrepancies in pulse oximetry. Our goal is clear — to enable the best care for every patient. We’re on it.
Accuracy based on study, not funded by Medtronic, that enrolled 146 healthy subjects in the 92–96% saturation range and examined paired readings from Nellcor™ N-595 and Masimo Radical 7™* pulse oximeters generated simultaneously. This study was not designed for head-to-head comparison of the respective devices.
In pulse oximeter clinical studies, Medtronic incorporates the Monk Skin Tone (MST) Scale — a more inclusive 10-pigmentation scale.
We’re always innovating because technology has the power to eliminate barriers to equitable care.
Explore how we are engineering for greater tech equity.
We’re partnering with professional and regulatory groups because health equity cannot be achieved alone.
Find out how we’re working with industry partners to accelerate progress.
We’re investing in education to empower healthcare providers to deliver the safest care for all patients.
Learn about resources, articles, educational content and more.
Listen to what led us to open a clinical physiology lab that recruits diverse participants that represent patients across all skin tones.
See independent evaluation at Open Oximetry, where each Nellcor™ system passed preliminary validation for patients of all skin tones.‡ The Open Oximetry project was created to improve the safety and precision of pulse oximeters in all populations.
Performs in accordance with 2013 FDA premarket notification submissions guidance and ISO 80601-2-61 (2017). Performance data from healthy volunteers may not accurately represent performance in real world patient populations. The information displayed here shall not be construed as an endorsement by Open Oximetry.
Learn how to bring more equitable outcomes to your patients.
At Medtronic, we understand that no issue in healthcare can be solved by a single group. We take our responsibility as a trusted industry leader to heart and seek out partners that are also driven to achieve equitable care for all. Together, we’re making collective progress in addressing technology bias in pulse oximetry.
The Nellcor™ pulse oximetry monitoring system should not be used as the sole basis for diagnosis or therapy and is intended only as an adjunct in patient assessment.
TM* Third–party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
† Based on study (not funded by Medtronic) that enrolled 146 healthy subjects in the 92-96% saturation range and examined paired readings from Nellcor™ N-595 and Masimo Radical 7™* pulse oximeters generated simultaneously. This study was not designed for head-to-head comparison of the respective devices.
‡ Performs in accordance with 2013 FDA premarket notification submissions guidance and ISO 80601-2-61 (2017). Performance data from healthy volunteers may not accurately represent performance in real world patient populations. The information displayed here shall not be construed as an endorsement by Open Oximetry.